Education
About Us
Working with TipRanks
Follow Us
Mink Therapeutics, Inc. (INKT)
:INKT
INKT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.56 - $13.79
Previous CloseN/A
Volume98.55K
Average Volume (3M)8.68K
Market Cap
$29.99M
Enterprise Value$27.93M
Total Cash (Recent Filing)$38.89M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.18
Next Earnings
May 07, 2025EPS Estimate
-0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.91
Shares Outstanding3,966,392
10 Day Avg. Volume6,097
30 Day Avg. Volume8,682
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.63
Forecast
1Y Price Target
$21.00Price Target Upside152.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
MiNK Therapeutics News
PremiumCompany Announcements
MiNK Therapeutics Reports 2024 Progress and Financials
PremiumCompany Announcements
MiNK Therapeutics’ Earnings Call Highlights Strategic Gains
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe majority of patients in the Phase 2 gastric study are now enrolled, with robust initial efficacy data expected to guide future developments.
Funding And Financial StrategyAcceptance of funding from NIAID for the upcoming GvHD study is considered a positive development for the company.
Bears Say
Data TransparencyNo data were provided on the study's primary or secondary endpoints.
Financial RiskReducing price target to $4/share to account for risks associated with potential future dilution.
---
Ownership Overview
3.12% Insiders
2.37% Mutual Funds
0.45% Other Institutional Investors
93.87% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
INKT FAQ
What was Mink Therapeutics, Inc.’s price range in the past 12 months?
Mink Therapeutics, Inc. lowest stock price was $4.56 and its highest was $13.79 in the past 12 months.
What is Mink Therapeutics, Inc.’s market cap?
Mink Therapeutics, Inc.’s market cap is $29.99M.
When is Mink Therapeutics, Inc.’s upcoming earnings report date?
Mink Therapeutics, Inc.’s upcoming earnings report date is May 07, 2025 which is in 22 days.
How were Mink Therapeutics, Inc.’s earnings last quarter?
Mink Therapeutics, Inc. released its earnings results on Mar 18, 2025. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.487 by -$0.133.
Is Mink Therapeutics, Inc. overvalued?
According to Wall Street analysts Mink Therapeutics, Inc.’s price is currently Undervalued.
Does Mink Therapeutics, Inc. pay dividends?
Mink Therapeutics, Inc. does not currently pay dividends.
What is Mink Therapeutics, Inc.’s EPS estimate?
Mink Therapeutics, Inc.’s EPS estimate is -0.71.
How many shares outstanding does Mink Therapeutics, Inc. have?
Mink Therapeutics, Inc. has 3,966,392 shares outstanding.
What happened to Mink Therapeutics, Inc.’s price movement after its last earnings report?
Mink Therapeutics, Inc. reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.487. Following the earnings report the stock price went down -3.286%.
Which hedge fund is a major shareholder of Mink Therapeutics, Inc.?
Currently, no hedge funds are holding shares in INKT
---
MiNK Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.00 (152.40% Upside)
$21.00 (152.40% Upside)
Hedge Fund Trend
Decreased
By 3.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-23.20%
12-Months-Change
Fundamentals
Return on Equity
78.50%
Trailing 12-Months
Asset Growth
25.67%
Trailing 12-Months
Company Description
Mink Therapeutics, Inc.
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
---
INKT Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant strategic and clinical advancements, including leadership strengthening and promising clinical progress in solid tumors and respiratory distress treatment. Financial improvements were noted, although concerns remain regarding cash position and funding uncertainty for the GvHD study.Read More>---
INKT Stock 12 Month Forecast
Average Price Target
$21.00
▲(152.40% Upside)
Technical Analysis
Tempest Therapeutics
―
Kezar Life Sciences
―
ALX Oncology Holdings
―
Surrozen
―
Connect Biopharma Holdings
―
Best Analysts Covering INKT
1 Year
1 Year Success Rate
5/13 ratings generated profit
1 Year Average Return
-17.19%
reiterated a buy rating 29 days ago
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of -17.19% per trade.
---